

# Kuen Chaang Uppertech Corp.

## 2023 Investor Conference

December 15. 2023



# Safe Harbor Notice

- Forward-looking statements in this presentation, which may include statements about its results of operations, financial condition or business prospects, are subject to significant risks and uncertainties and are based on current expectations.
- Except as required by law, Kuen Chaang undertakes no obligation to update or revise any forward-looking statements with respect to the content of this presentation, whether as a result of new information, future events or otherwise.
- Any financial information contained here within is presented in conformity with International Financial Reporting Standards (IFRSs).
- You are urged to review carefully the information provided herein. This information shall not be distributed, reproduced or disclosed in whole or in part without prior written permission of Kuen Chaang Uppertech Corp.

# Agenda

**Group's Overview**

**Financial Results**

**Business Outlook**

**Q & A**

# Group's Overview History

1998年

- 成立堃昶股份有限公司，主要業務為電子零組件銷售，半導體之代理經銷。

2003年

- 獲主管機關通過核准上櫃。

2012年

- 取得仙桃牌商標及藥品許可證，百年漢方食品化，結合現代科技，積極擴展藥食同源之食品業務。

2017年

~2019年

- 因大陸市場的不確定性，堃昶公司轉為聚焦以信用良好的台商為主。

2022

~2023年

- 對100%轉投資子公司仁壽藥業有限公司增資至資本額新台幣2,000萬元整，並取得藥商資格。
- 經向衛福部中藥司申請，已核可「保血平丸」恢復生產製造及銷售。

# Group's Overview **Major Client**



## Concise Balance Sheet

	Unit : NT\$ Thousand			
Item	2020	2021	2022	2023 Q3
Current assets	1,234,534	1,376,882	1,297,936	1,243,020
Non-current assets	297,336	276,154	270,692	269,929
Total Assets	1,531,870	1,653,036	1,568,628	1,512,949
Current liabilities	226,255	272,576	173,715	171,739
Non-current liabilities	4,482	3,618	9,294	14,765
Total Liabilities	230,737	276,194	183,009	186,504
Total Equity	1,301,133	1,376,842	1,385,619	1,326,445
Current ratio ( % )	545.64	505.14	747.16	723.78
A/R turnover ratio ( times )	3.61	4.59	3.92	3.12
A/R turnover days	101.20	79.52	73.11	116.99
Inventory turnover ( times )	6.15	4.33	2.35	1.66

# Financial Results

## Concise Statement of Income


				Unit : NT\$ Thousand
Item	2020	2021	2022	2023 Q1-Q3
Operating revenue	1,035,163	1,610,841	1,250,708	518,703
COGS	993,206	1,454,581	1,217,517	595,990
Gross profit	41,957	156,260	33,191	(77,287)
Operating expenses	75,541	83,847	65,572	44,259
Operating income	(33,584)	72,413	(32,381)	(121,546)
Profit before tax	(29,164)	80,468	16,812	(67,478)
Net profit	(29,245)	75,706	8,824	(58,956)
EPS	(0.25)	0.64	0.07	(0.05)

# Financial Results

## Consolidated revenue (by quarter)

Unit : NT\$ Thousand

Q / Y	2020	2021	2022	2023
Q1	273,837	322,871	375,296	211,487
Q2	240,989	392,246	328,663	127,433
Q3	225,767	431,764	344,547	179,783
Q4	294,570	463,960	202,202	
Total	1,035,163	1,610,841	1,250,708	518,703





# 2024 Business Outlook

- **KUEN CHANG UPPERTECH CORP. :**

Continue to negotiate for new product line agents

- **Renshou Pharmaceutical Co., Ltd. :**

Develop new products and expand sales channels simultaneously

- Note:

For product information, please visit the Sentao official website.

- <https://www.sen-tao.com/pages/history>



